LB Pharmaceuticals Inc Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LBRX research report →
Range $35 – $80
Price Chart
About the company
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
- CEO
- Heather D. Turner
- IPO
- 2025
- Employees
- 27
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on LBRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.26B
- P/E
- -8.72
- PEG
- -0.42
- P/S
- 0.00
- P/B
- 3.19
- EV/EBITDA
- -7.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -39.50%
- ROIC
- -35.93%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-30,404,000
- Net Income
- $-25,205,000+60.1%
- EPS
- $-1.00+94.4%
- OCF Growth
- +33.6%
- FCF Growth
- +34.5%
- 52W High
- $50.16
- 52W Low
- $15.19
- 50D MA
- $39.61
- 200D MA
- $33.96
- Beta
- 0.42
- RSI (14)
- 44
- Avg Volume
- 371.95K
No earnings-call transcripts are available for LBRX yet.
- Free Float
- 82.1%
- Shares Outstanding
- 32.36M
- Float Shares
- 26.56M
of shares held by institutions
117 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Deep Track Capital, LP | 3.35M | 0 |
| Blackrock, Inc. | 2.35M | ▼ 387.52K |
| Ra Capital Management, L.P. | 2.21M | 0 |
| Trails Edge Capital Partners, LP | 1.52M | ▲ 203.66K |
| Commodore Capital LP | 1.50M | 0 |
| Tcg Crossover Management, LLC | 1.45M | ▼ 392.18K |
| Jpmorgan Chase & Co | 1.44M | ▼ 53.08K |
| Caligan Partners LP | 1.44M | 0 |
| Spruce Street Capital LP | 1.40M | ▲ 28.62K |
| Vanguard Group Inc | 1.11M | ▲ 1.11M |
| Fmr LLC | 1.10M | ▲ 915.00K |
| Vanguard Capital Management LLC | 1.10M | ▲ 128.72K |
Held by 192 ETFs
Biggest fund positions in LBRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 9, 26 | Miller Joseph M | other | 200,000 |
| Oct 9, 26 | Kozauer Susan Gani | other | 200,000 |
| Sep 14, 26 | Kozauer Susan Gani | other | 0 |
| Sep 2, 26 | Miller Joseph M | other | 0 |
| Jul 30, 26 | Deep Track Biotechnology Master Fund, Ltd. | buy | 286,205 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LBRX coverage
Recent articles, reports, and earnings notes.
No research on LBRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LBRX report →Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction
seekingalpha.com · Nov 8
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 5
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
marketbeat.com · Oct 27
LB Pharmaceuticals to Participate in Upcoming Investor Events
globenewswire.com · Oct 15
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
globenewswire.com · Oct 6
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $49.62
defenseworld.net · Sep 28
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
seekingalpha.com · Sep 18
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
globenewswire.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.